Eylea Post Marketing Surveillance(PMS)

Bayer3,206 enrolled

Overview

The objective of this PMS is to gain information about safety and efficacy in real practice as a regulatory commitment required by MFDS

Study Type

OBSERVATIONAL

Enrollment

3,206

Conditions

Macular Degeneration

Interventions

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)DRUG

Patients in daily life clinical practice treatment receiving EYLEA according to indication on the label.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients determined to start EYLEA treatment * Patients who agree and sign informed consent * Patients who receive EYLEA treatment for the first time * Patients who meet one of the following * Patients diagnosed by physician as having neovascular (wet) age-related macular degeneration wAMD * Patients diagnosed by physician as having visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO) * Patients diagnosed as having visual impairment due to diabetic macular edema (DME) * Patients diagnosed as having visual impairment due to myopic choroidal neovascularization (mCNV) Exclusion Criteria: * Patients who have received anti-VEGF therapy within 90 days * Patients who are contraindicated based on the approved product label * Ocular or periocular infection * Active severe intraocular inflammation * Known hypersensitivity to any ingredient of this drug

Locations (1)

Many Locations

Multiple Locations, South Korea

Outcomes

Primary Outcomes

Adverse events (AEs) [including serious adverse events (SAEs) and ocular AEs, especially AEs due to intravitreal injection procedure] and adverse drug reactions (ADRs)

Time frame: 4 months

Secondary Outcomes

Measurement of BCVA (prior to injection and performing other ocular assessments) by eye chart. [BCVA: Best Corrected Visual Acuity]